Tasigna — Blue Cross Blue Shield of Kansas
Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase
Preferred products
- imatinib (generic)
- dasatinib (generic)
Initial criteria
- Target Agent(s) will be approved when ALL of the following general PA criteria are met as above, including FDA or compendia-supported indication, treatment history, and preferred status.
- If requested agent is Bosulif or Tasigna for CML, patient has been previously treated with Bosulif or Tasigna for CML.